Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017, Article ID 4130824, 12 pages
https://doi.org/10.1155/2017/4130824
Research Article

Amifostine Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting Apoptosis and Oxidative Stress

Department of Cardiology, The Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou 325000, China

Correspondence should be addressed to Kang-ting Ji; moc.361@tgnikij

Received 24 November 2016; Revised 23 January 2017; Accepted 14 February 2017; Published 14 March 2017

Academic Editor: Vincenzo Lionetti

Copyright © 2017 Shao-ze Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. A. Cabrera-Fuentes, J. Aragones, J. Bernhagen et al., “From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on ‘New frontiers in cardiovascular research’,” Basic Research in Cardiology, vol. 111, no. 6, article 69, 2016. View at Publisher · View at Google Scholar
  2. E. Donnarumma, M. J. Ali, A. M. Rushing et al., “Zofenopril protects against myocardial ischemia-reperfusion injury by increasing nitric oxide and hydrogen sulfide bioavailability,” Journal of the American Heart Association, vol. 5, no. 7, Article ID e003531, 2016. View at Publisher · View at Google Scholar
  3. Y. Yang, Z. Ma, W. Hu et al., “Caveolin-1/-3: therapeutic targets for myocardial ischemia/reperfusion injury,” Basic Research in Cardiology, vol. 111, no. 4, article 45, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Gurewich, “Thrombolysis: a critical first-line therapy with an unfulfilled potential,” The American Journal of Medicine, vol. 129, no. 6, pp. 573–575, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Bedenis, A. Lethaby, H. Maxwell, S. Acosta, and M. H. Prins, “Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery,” The Cochrane Database of Systematic Reviews, vol. 2, Article ID CD000535, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Al-Lamee, J. Davies, and I. S. Malik, “What is the role of coronary angioplasty and stenting in stable angina?” BMJ, vol. 352, article i205, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. T. K. Kim, J. J. Min, Y. J. Cho et al., “Effects of delayed remote ischemic preconditioning on peri-operative myocardial injury in patients undergoing cardiac surgery—a randomized controlled trial,” International Journal of Cardiology, vol. 227, pp. 511–515, 2017. View at Publisher · View at Google Scholar
  8. F. Bellanti, L. Mirabella, D. Mitarotonda et al., “Propofol but not sevoflurane prevents mitochondrial dysfunction and oxidative stress by limiting HIF-1α activation in hepatic ischemia/reperfusion injury,” Free Radical Biology and Medicine, vol. 96, pp. 323–333, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Zhang, S. Cao, S. Deng, G. Yao, and T. Yu, “Ischemic postconditioning and pinacidil suppress calcium overload in anoxia-reoxygenation cardiomyocytes via down-regulation of the calcium-sensing receptor,” PeerJ, vol. 4, Article ID e2612, 2016. View at Publisher · View at Google Scholar
  10. F. M. Buarque De Gusmão, C. Becker, M. H. Catelli Carvalho, and L. F. Monteiro Barros, “Angiotensin II inhibition during myocardial ischemia-reperfusion in dogs: effects on leukocyte infiltration, nitric oxide synthase isoenzymes activity and left ventricular ejection fraction,” International Journal of Cardiology, vol. 100, no. 3, pp. 363–370, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Zhang, J. Wang, and J. Pan, “Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats,” Drug Delivery, vol. 23, no. 9, pp. 3696–3703, 2016. View at Publisher · View at Google Scholar
  12. M. Hofer, M. Falk, D. Komůrková et al., “Two new faces of amifostine: protector from DNA Damage in normal cells and inhibitor of DNA repair in cancer cells,” Journal of Medicinal Chemistry, vol. 59, no. 7, pp. 3003–3017, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. C. R. Culy and C. M. Spencer, “Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome,” Drugs, vol. 61, no. 5, pp. 641–684, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Melis, R. Valkema, E. P. Krenning, and M. De Jong, “Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration,” Journal of Nuclear Medicine, vol. 53, no. 5, pp. 749–753, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Pang, Y. Cai, E. H. Tang et al., “Cox-2 inhibition protects against hypoxia/reoxygenation-induced cardiomyocyte apoptosis via akt-dependent enhancement of inos expression,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3453059, 17 pages, 2016. View at Publisher · View at Google Scholar
  16. M. Kawaguchi, M. Takahashi, T. Hata et al., “Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury,” Circulation, vol. 123, no. 6, pp. 594–604, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Li, M. Wu, L. Tang et al., “Novel curcumin analogue 14p protects against myocardial ischemia reperfusion injury through Nrf2-activating anti-oxidative activity,” Toxicology and Applied Pharmacology, vol. 282, no. 2, pp. 175–183, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. M. C. Woodall, B. P. Woodall, E. Gao, A. Yuan, and W. J. Koch, “Cardiac fibroblast GRK2 deletion enhances contractility and remodeling following ischemia/reperfusion injury,” Circulation Research, vol. 119, no. 10, pp. 1116–1127, 2016. View at Publisher · View at Google Scholar
  19. Y. Mo, L. Tang, Y. Ma, and S. Wu, “Pramipexole pretreatment attenuates myocardial ischemia/reperfusion injury through upregulation of autophagy,” Biochemical and Biophysical Research Communications, vol. 473, no. 4, pp. 1119–1124, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. E. J. Lesnefsky, Q. Chen, B. Tandler, and C. L. Hoppel, “Mitochondrial dysfunction and myocardial ischemia-reperfusion: implications for novel therapies,” Annual Review of Pharmacology and Toxicology, vol. 57, no. 1, pp. 535–565, 2017. View at Publisher · View at Google Scholar
  21. H. Pei, Y. Yang, H. Zhao et al., “The role of mitochondrial functional proteins in ROS production in ischemic heart diseases,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 5470457, 8 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Bagheri, V. Khori, A. M. Alizadeh, S. Khalighfard, S. Khodayari, and H. Khodayari, “Reactive oxygen species-mediated cardiac-reperfusion injury: mechanisms and therapies,” Life Sciences, vol. 165, pp. 43–55, 2016. View at Publisher · View at Google Scholar
  23. F. He, J. Li, Z. Liu, C. C. Chuang, W. Yang, and L. Zuo, “Redox mechanism of reactive oxygen species in exercise,” Frontiers in Physiology, vol. 7, article 486, 2016. View at Publisher · View at Google Scholar
  24. N. Pavón, A. Cabrera-Orefice, J. C. Gallardo-Pérez et al., “In female rat heart mitochondria, oophorectomy results in loss of oxidative phosphorylation,” Journal of Endocrinology, vol. 232, no. 2, pp. 221–235, 2016. View at Publisher · View at Google Scholar
  25. F. Perros, S. Günther, B. Ranchoux et al., “Mitomycin-induced pulmonary veno-occlusive disease: evidence from human disease and animal models,” Circulation, vol. 132, no. 9, pp. 834–847, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Feng, D. E. Smith, D. P. Normolle et al., “A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy,” International Journal of Radiation Oncology Biology Physics, vol. 83, no. 5, pp. 1441–1447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Chronidou, E. Apostolakis, I. Papapostolou et al., “Beneficial effect of the oxygen free radical scavenger amifostine (WR-2721) on spinal cord ischemia/reperfusion injury in rabbits,” Journal of Cardiothoracic Surgery, vol. 4, article 50, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Viktorija, S. L. J. D. Dragojevic-Simica, R. Dubravko, M. Zarko, M. Vesna, and P. Nikola, “Amifostine protection against doxorubicin cardiotoxicity in rats,” Anticancer Drugs, vol. 15, no. 2, pp. 69–78, 2004. View at Google Scholar
  29. J. Jia, L. Zhang, X. Shi et al., “SOD2 mediates amifostine-induced protection against glutamate in PC12 cells,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 4202437, 11 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. G. F. Hatoum, B. Nevaldine, T. Bhavsar, Q. Phung, and P. J. Hahn, “WR-1065, the active form of amifostine, protects HL-60 cells but not peripheral blood mononuclear cells from radiation and etoposide-induced apoptosis,” International Journal of Radiation Oncology Biology Physics, vol. 59, no. 3, pp. 844–851, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. Y.-C. Ma, Y. Ke, X. Zi et al., “Induction of the mitochondria-mediated apoptosis in human esophageal cancer cells by DS2, a newly synthetic diterpenoid analog, is regulated by Bax and caused by generation of reactive oxygen species,” Oncotarget, vol. 7, no. 52, pp. 86211–86224, 2016. View at Publisher · View at Google Scholar